{"name": "SuperGen",
 "permalink": "supergen",
 "crunchbase_url": "http://www.crunchbase.com/company/supergen",
 "homepage_url": "http://www.supergen.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": 85,
 "founded_year": 1991,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": null,
 "alias_list": "",
 "email_address": "",
 "phone_number": "925-560-0100",
 "description": "pharmaceutical company",
 "created_at": "Wed Dec 24 12:27:59 UTC 2008",
 "updated_at": "Fri Apr 08 04:50:08 UTC 2011",
 "overview": "\u003Cp\u003ESuperGen, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of therapies to treat patients with cancer. Products in Development MP-470\u00e2\u20ac\u201dDNA Repair Suppressor: MP-470 is a multi-targeted Tyrosine Kinase Inhibitor that is specific for mutant forms of c-kit, PDGFRa, and FLT3. These protein kinase targets are involved in the growth and proliferation of cancer cells. MP-470 is also a suppressor of Rad51, a DNA repair protein which is involved in resistance to various chemotherapy agents and radiation.\u003C/p\u003E\n\n\u003Cp\u003ESuperGen, Inc. was founded in 1991.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       60],
      "assets/images/resized/0007/2509/72509v1-max-150x150.png"],
     [[180,
       72],
      "assets/images/resized/0007/2509/72509v1-max-250x250.png"],
     [[180,
       72],
      "assets/images/resized/0007/2509/72509v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [{"title": "Meeting Logistics, Web Conference",
    "is_past": true,
    "provider":
     {"name": "Birchwood Group",
      "permalink": "birchwood-group",
      "image":
       {"available_sizes":
         [[[150,
            21],
           "assets/images/resized/0003/2400/32400v2-max-150x150.png"],
          [[250,
            35],
           "assets/images/resized/0003/2400/32400v2-max-250x250.png"],
          [[450,
            63],
           "assets/images/resized/0003/2400/32400v2-max-450x450.png"]],
        "attribution": null}}}],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [{"price_amount": 55000000.0,
    "price_currency_code": "USD",
    "term_code": "cash_and_stock",
    "source_url": "http://www.fiercebiotech.com/story/supergen-snags-uks-astex-55m-ma-deal/2011-04-07?utm_medium=rss\u0026utm_source=rss",
    "source_description": "SuperGen snags UK's Astex in a $55M M\u0026A deal",
    "acquired_year": 2011,
    "acquired_month": 4,
    "acquired_day": 7,
    "company":
     {"name": "Astex",
      "permalink": "astex",
      "image":
       {"available_sizes":
         [[[150,
            51],
           "assets/images/resized/0012/9731/129731v1-max-150x150.jpg"],
          [[200,
            69],
           "assets/images/resized/0012/9731/129731v1-max-250x250.jpg"],
          [[200,
            69],
           "assets/images/resized/0012/9731/129731v1-max-450x450.jpg"]],
        "attribution": null}}}],
 "offices":
  [{"description": "HQ",
    "address1": "4140 Dublin Boulevard",
    "address2": "Suite 200",
    "zip_code": "94568",
    "city": "Dublin",
    "state_code": "CA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        121],
       "assets/images/resized/0007/2510/72510v1-max-150x150.jpg"],
      [[250,
        202],
       "assets/images/resized/0007/2510/72510v1-max-250x250.jpg"],
      [[450,
        364],
       "assets/images/resized/0007/2510/72510v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}